Skip to main content

Advertisement

Table 1 Demographic and clinical characteristics of the study participants

From: APACHE-II score for anti-tuberculosis tolerance in critically ill patients: a retrospective study

Parameter Drug withdrawal group (n = 147) Therapy completion group (n = 173) P
Demographic characteristics
 Age (years) 65 (2–94) 62 (17–90) 0.24
 Male 118 (80.3%) 138 (79.8%) 0.91
Tuberculosis characteristics
 Pulmonary tuberculosis 131 (89.1%) 153 (88.4%) 0.85
 Sputum smear positive 98 (66.7%) 105 (60.7%) 0.27
 Extrapulmonary tuberculosis 51 (34.7%) 83 (48.05) 0.02
 First treatment 116 (78.9%) 145 (83.8%) 0.26
Comorbidities
 Diabetes mellitus 26 (17.7%) 32 (18.5%) 0.85
 Hypertension 42 (28.6%) 40 (23.1%) 0.27
 Coronary heart disease 23 (15.6%) 17 (9.8%) 0.12
 Chronic heart failure 37 (25.2%) 33 (19.1%) 0.19
 Atrial fibrillation 12 (8.2%) 9 (5.2%) 0.29
 Chronic renal failure 14 (9.5%) 7 (4.0%) 0.049
 Lung cancer 3 (2.0%) 5 (2.9%) 0.63
 Other malignant tumors 12 (8.2%) 10 (5.8%) 0.40
 COPD 31 (21.1%) 21 (12.1%) 0.03
 Bronchiectasis 5 (3.4%) 4 (2.3%) 0.56
 Autoimmune disease 12 (8.2%) 15 (8.7%) 0.87
 Neurological disorders 20 (13.6%) 18 (10.4%) 0.38
 Viral hepatitis B 7 (4.8%) 14 (8.1%) 0.23
Previous medical interventions
 Long-term steroids 12 (8.2%) 12 (6.9%) 0.68
 Long-term immunosuppressants 2 (1.4%) 4 (2.3%) 0.53
 Mechanical ventilation 119 (81.0%) 124 (71.7%) 0.053
Blood test results
 White blood cell (109/L) 9.8 (1.5–35.5) 10.4 (0.4–41.2) 0.27
 Platelet (109/L) 158 (2–576) 193 (12–723) 0.06
 Hemoglobin (g/L) 92 (41–150) 104 (38–160) 0.001
 Total bilirubin (μmol/L) 12.1 (2.5–269.6) 12.9 (1–92.2) 0.40
 Direct bilirubin (μmol/L) 5.8 (0.1–131.4) 6.6 (0.1–65.1) 0.24
 Indirect bilirubin (μmol/L) 5.1 (0.3–138.2) 5.4 (0.1–49) 0.54
 Uric acid (μmol/L) 209 (29–1102) 225 (1–831) 0.21
 Urea nitrogen (mmol/L) 6.4 (0.9–34.6) 5.9 (1.4–75.8) 0.07
 Total protein (g/L) 57.3 (26–83) 56.7 (30.1–84.3) 0.62
 Albumin (g/L) 27.3 (10.6–47.4) 28.0 (15.4–47.0) 0.15
 Globulin (g/L) 28.4 (15.4–46) 27.3 (10.7–50.6) 0.08
 Aspartate aminotransferase (U/L) 33 (7–1241) 28 (6–2971) 0.21
 Alanine aminotransferase (U/L) 19 (3–461) 22 (2–757) 0.23
 Alkaline phosphatase (U/L) 94 (28–393) 84 (25–927) 0.12
 Gamma-glutamyltransferase (U/L) 49 (10–813) 44 (10–991) 0.92
 Prealbumin (mg/L) 86 (4–272) 105 (8–394) 0.26
 Retinol binding protein (mg/L) 12.0 (1.1–73.8) 12.3 (0.5–66.0) 0.51
 Fructosamine (mmol/L) 1.47 (0.70–3.06) 1.46 (0.81–4.02) 0.62
 Immunoglobulin A (g/L) 2.96 (0.50–8.82) 2.75 (0.22–6.15) 0.49
 Immunoglobulin G (g/L) 12.5 (4.4–24.5) 11.6 (3.0–25.8) 0.19
 Immunoglobulin M (g/L) 1.00 (0.35–3.39) 0.93 (0.28–3.52) 0.60
 Complement component C3 (g/L) 0.77 (0.08–1.64) 0.89 (0.20–2.51) 0.15
 Complement component C4 (g/L) 0.24 (0.02–0.47) 0.25 (0.07–0.64) 0.40
 Cancer antigen CA-125 (kU/L) 86.0 (7.4–1977.2) 74.3 (3.3–1241.5) 0.54
 CD3 (%) 63.0 (35.6–94.1) 57.9 (26.3–90.5) 0.09
 CD4 (%) 33.6 (4.61–64.5) 29.4 (6.67–73.1) 0.02
 CD8 (%) 22.3 (3.3–56.9) 22.0 (4.66–76.2) 0.81
 CD4/CD8 ratio 1.54 (0.25–13.58) 1.4 (0.13–11.01) 0.23
 CD19 (%) 9.3 (0.1–46.3) 10.2 (0.3–48.3) 0.27
 CD16 and CD56 (%) 11.0 (0.17–43.6) 11.5 (0.1–60.5) 0.36
Illness severity scales
 APACHE-II score 21 (3–52) 17 (4–42) < 0.001
 SOFA score 6 (0–17) 5 (0–18) 0.10
  1. Data are presented as median (interquartile range) or n (%). COPD chronic obstructive pulmonary disease, SOFA Sequential Organ Failure Assessment